Seeking Alpha

BridgeBio starts dosing in phase 1/2 trial of BBP-398, Opdivo combo for solid tumors

BridgeBio Pharma (NASDAQ:BBIO) said the first patient with non-small cell lung cancer (NSCLC) was dosed in a phase 1/2 trial of BBP-398 with Bristol Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) to ...
Pharmabiz

LianBio begins patient dosing in phase 1 trial of SHP2 inhibitor BBP-398 in combo with osimertinib to treat NSCLC with EGFR mutations

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced the first patient has been dosed in its phase 1 clinical trial ...
Pharmabiz

BridgeBio inks clinical collaboration with Amgen to study BBP-398 in combo with Lumakras in advanced solid tumours with KRAS G12C mutation

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, announced a non-exclusive clinical collaboration with Amgen Inc. (Amgen) to evaluate the combination of BBP-398, a potentially ...